Welcome to our dedicated page for Teva Pharm news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharm stock.
Teva Pharmaceutical Industries Limited reports developments across its global pharmaceutical business, including complex generic medicines, biosimilars, pharmacy brands, and innovative medicines in neuroscience and immunology. News commonly covers financial results, investor conference presentations, R&D updates, regulatory milestones, and product or patient-support launches tied to brands and candidates such as UZEDY, PONLIMSI, and proposed biosimilars.
As an Israel-based issuer with ADSs traded under TEVA, company updates also address ADR-relevant investor communications, operating outlook materials, partnerships, and strategy around a generics platform supporting a broader biopharmaceutical portfolio.
Teva (NYSE: TEVA) posted its Q1 2026 Aide Memoire to the Investors page to help investors ahead of first-quarter results. The document compiles previously disclosed public information, management commentary and select independent data.
Teva expects to release Q1 2026 results on April 29, 2026 at 7:00 AM ET, with a conference call at 8:00 AM ET.
Teva (NYSE: TEVA) will release its first quarter 2026 financial results on April 29, 2026 at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET the same day. Registration is required for phone participation and a replay will be available within 24 hours on Teva's investor website.
Teva (NYSE: TEVA) and Blackstone Life Sciences announced a $400 million strategic funding agreement over four years to support development of duvakitug, a human monoclonal antibody targeting TL1A in phase 3 studies for ulcerative colitis and Crohn’s disease.
BXLS may earn regulatory and commercial milestones plus low single-digit royalties on worldwide sales, and Teva remains co-developer/co-commercializer with Sanofi subject to regulatory approval.
Teva (NYSE: TEVA) announced that President and CEO Richard Francis will participate in three investor conferences in March 2026: UBS European Healthcare Conference (Mar 3, investor meetings only), Leerink Partners Global Healthcare Conference (Mar 9, 10:00 AM ET, webcast fireside chat), and Barclays 28th Annual Global Healthcare Conference (Mar 10, 8:00 AM ET, webcast fireside chat).
Live webcasts and archived recordings (available within 24 hours, accessible for up to 30 days) will be hosted on Teva's Investor Relations website.
Teva (NYSE: TEVA) announced FDA acceptance of its New Drug Application for TEV-'749, an investigational once-monthly subcutaneous olanzapine extended-release injectable suspension on Feb 20, 2026.
The NDA is supported by Phase 3 SOLARIS Week 56 results showing efficacy and safety consistent with existing olanzapine formulations and no evidence requiring post-injection monitoring; TEV-'749 uses Medincell's SteadyTeq sustained-release copolymer technology.
Teva (NYSE:TEVA) and Sanofi reported positive RELIEVE UCCD LTE phase 2b results for investigational duvakitug, showing durable clinical and endoscopic efficacy maintained for 44 weeks in patients with ulcerative colitis and Crohn’s disease who responded to induction.
At week 44, clinical remission in UC was 58% (900 mg) and 47% (450 mg); endoscopic response in CD was 55% (900 mg) and 41% (450 mg). Safety was consistent with induction; detailed results will be presented at a medical meeting. Teva will host an investor call and webcast on Feb 17, 2026.
Teva (NYSE:TEVA) reported 2025 revenues of $17.3 billion, a 4% YoY increase (3% in local currency), marking its third consecutive year of growth. Key innovative brands surpassed $3 billion (+35% YoY LC), with AUSTEDO $2.26B and AJOVY $673M. Gross profit rose 11% to $8.94B. Free cash flow was $2.40B, debt reduced via $1.812B senior note repayment, and 2026 guidance forecasts revenues of $16.4–$16.8B and non-GAAP diluted EPS of $2.57–$2.77.
Teva (NYSE:TEVA) on Jan 27, 2026 announced a partnership with actor and advocate Will Forte to raise awareness of Huntington’s disease (HD) through the Honestly HD program.
The campaign highlights HD symptoms including chorea—involuntary movements affecting up to 90% of people with HD—and directs people to educational resources at HonestlyHD.com. The release notes HD affects more than 41,000 people in the U.S.
Teva (NYSE: TEVA) announced publication in the New England Journal of Medicine of Phase 3 SPACE trial results showing AJOVY (fremanezumab-vfrm) significantly reduced monthly migraine days and monthly headache days versus placebo in children and adolescents with episodic migraine.
Key results: MMD reduction 2.5 days with AJOVY vs 1.4 days placebo (difference 1.1 days; P=0.02); MHD reduction 2.6 vs 1.5 days (difference 1.1 days; P=0.02); ≥50% MMD responder rate 47.2% vs 27.0% (P=0.002). The 3-month trial enrolled 237 patients. The data supported FDA approval in August 2025 for preventive treatment of episodic migraine in patients aged 6–17 years weighing ≥45 kg. No new safety signals identified.
Teva (NYSE: TEVA) will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026 at 8:15 AM PT to review its Pivot to Growth strategy, 2025 results and outlook through 2030. Key 2025 outlook: revenues $16.8–$17.0B, operating margin ~26.2%–27.1%, adjusted EBITDA $4.8–$5.0B, diluted EPS $2.55–$2.65, and free cash flow $1.6–$1.9B. Company expects additional contribution from duvakitug milestones (≈$500M revenue, ~$400M EBITDA, ~$500M FCF). Multi-year targets include low-single-digit revenue growth in 2027, operating profit ~30% in 2027, and free cash flow >$3.5B by 2030.